Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Clinical Pharmacology & Therapeutics2018Vol. 103(4), pp. 574–581
Citations Over TimeTop 1% of 2018 papers
Elizabeth J. Phillips, Chonlaphat Sukasem, Michelle Whirl‐Carrillo, Daniel J. Müller, Henry M. Dunnenberger, Wasun Chantratita, Barry R. Goldspiel, Yuan‐Tsong Chen, Bruce Carleton, Alfred L. George, Taisei Mushiroda, Teri E. Klein, Roseann S. Gammal, Munir Pirmohamed
Abstract
The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.
Related Papers
- → Substituting Carbamazepine with Oxcarbazepine Increases Citalopram Levels. A Report on Two Cases(2007)38 cited
- → Efficacy of Carbamazepine and Oxcarbazepine for Treating Trigeminal Neuralgia(2023)3 cited
- → [Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis].(2001)5 cited
- → Prophylactic Treatment of Affective Disorders with Carbamazepine and Oxcarbazepine: An Open Clinical Trial(1985)5 cited
- Comparative study the single drug treatment with Oxcarbazepine and Carbamazepine on children with partial epilepse(2008)